QBW251 placebo-controlled phase 2 study in non-cystic fibrosis bronchiectasis

Phase 2, randomised, double-blind trial in bronchiectasis comparing Icenticaftor with Placebo (2 arms). Primary endpoint: Change from baseline in bacterial load of potentially pathogenic microorganisms in spontaneous sputum at week 12. Status: unknown.